Cancer survivor (in remission)
Confirmed remission from prior cancer — considering peptides for recovery, body composition, or general aging. Active oncology is a separate, hard-refusal situation.
What changes during this transition
This axis is for users IN REMISSION — active oncology is a different conversation that warrants hard refusal until clearance from the oncology team (Juno's AI surface refuses active-oncology contexts at the profile gate). For survivors, the editorial concern with most growth-supporting peptides is theoretical-but-real: IGF-1 elevation has been associated with cancer-incidence signals in observational cohorts; growth-factor stimulation in users with prior cancer history may interact with residual cell populations. Thymosin alpha-1 is the **counter-case** in this trigger — unlike the growth-factor peptides, TA-1 has actual oncology adjunct evidence (HCC, melanoma, NSCLC immune-support trials) and a favorable safety profile across decades of approved-market use abroad. BPC-157, CJC-1295, and TB-500 are listed because survivors will ask about them — substrate framing keeps the concerns explicit: target mid-range IGF-1 (not upper-quartile), defer where possible until clearance windows are met, and oncology coordination is the precondition.
Important caveat
Oncology team coordination is the precondition for ANY peptide layered on cancer-survivor status — not optional. The conservative protocol for growth-factor-stimulating peptides is to wait at least 5 years from remission and to confirm with oncology before starting. **Melanotan-2 is OMITTED from this list** — for users with personal or family history of melanoma specifically, MT-2's melanocyte-stimulation mechanism is most directly relevant and case reports describe accelerated mole changes; it's substrate-only, not surfaced for discovery. Different cancer types carry different mechanism-specific concerns (hormone-responsive cancers + GH-axis; estrogen-responsive + any HPG-axis peptide); the editorial here can't substitute for cancer-type-specific oncology input.
Peptides editorially relevant to cancer survivor (in remission)
4 peptides from the library — each evidence-tiered honestly.
- Thymosin Alpha-1Tier 2
Immunomodulatory peptide
Approved in 30+ countries for chronic hepatitis B and C and as a sepsis adjunct in critically ill patients — but not in the US. Evidence quality varies sharply by indication, and the popular 'general immune support' framing has no clinical backing.
- BPC-157Tier 3
Gastric pentadecapeptide
Extensively studied in rodents for tissue healing across tendon, gut, vascular, and CNS injury models. Human evidence is essentially absent — community framing far outpaces the data.
- CJC-1295Tier 3
GHRH analog
Long-acting GHRH analog often paired with a GHRP. Strong PK data in humans; outcome data is limited.
- TB-500Tier 3
Thymosin Beta-4 fragment
Animal-data peptide marketed as a tissue-repair adjunct. No published human RCTs for musculoskeletal indications.
Want this list to grow? The library is editorial — if there’s a peptide you think belongs on this page with documented or mechanistically-clear evidence, send us a note with the citation and we’ll review it under the same evidence-tier discipline as every other entry.